Merck (MRK) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY24 Guidance

Merck (NYSE: MRK) reported Q4 EPS of $0.03, $0.14 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $14.6 billion versus the consensus estimate of $14.47 billion.

GUIDANCE:

Merck sees FY2024 EPS of $8.44-$8.59, versus the consensus of $8.42. Merck sees FY2024 revenue of $62.7-64.2 billion, versus the consensus of $63.5 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• FDA approves Merck and Eisai kidney cancer combination therapy
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance